AU550774B2 - 1-aryl-2-aminomethyl cyclopropane carboxylates - Google Patents

1-aryl-2-aminomethyl cyclopropane carboxylates

Info

Publication number
AU550774B2
AU550774B2 AU85086/82A AU8508682A AU550774B2 AU 550774 B2 AU550774 B2 AU 550774B2 AU 85086/82 A AU85086/82 A AU 85086/82A AU 8508682 A AU8508682 A AU 8508682A AU 550774 B2 AU550774 B2 AU 550774B2
Authority
AU
Australia
Prior art keywords
atom
aryl
alkyl group
lower alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU85086/82A
Other languages
English (en)
Other versions
AU8508682A (en
Inventor
Bernard Bonnaud
Henri Cousse
Michel Morre
Gilbert Mouzin
Antoine Stenger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9259785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU550774(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pierre Fabre SA filed Critical Pierre Fabre SA
Publication of AU8508682A publication Critical patent/AU8508682A/en
Application granted granted Critical
Publication of AU550774B2 publication Critical patent/AU550774B2/en
Assigned to PIERRE FABRE S.A. reassignment PIERRE FABRE S.A. Alteration of Name(s) in Register under S187 Assignors: PIERRE FABRE S.A.
Assigned to PIERRE FABRE MEDICAMENT reassignment PIERRE FABRE MEDICAMENT Alteration of Name(s) in Register under S187 Assignors: PIERRE FABRE S.A.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU85086/82A 1981-06-23 1982-06-22 1-aryl-2-aminomethyl cyclopropane carboxylates Expired AU550774B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8112312A FR2508035A1 (fr) 1981-06-23 1981-06-23 Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
FR8112312 1981-06-23

Publications (2)

Publication Number Publication Date
AU8508682A AU8508682A (en) 1983-01-06
AU550774B2 true AU550774B2 (en) 1986-04-10

Family

ID=9259785

Family Applications (1)

Application Number Title Priority Date Filing Date
AU85086/82A Expired AU550774B2 (en) 1981-06-23 1982-06-22 1-aryl-2-aminomethyl cyclopropane carboxylates

Country Status (11)

Country Link
US (1) US4478836A (OSRAM)
EP (1) EP0068999B1 (OSRAM)
JP (1) JPS584752A (OSRAM)
AT (1) ATE13422T1 (OSRAM)
AU (1) AU550774B2 (OSRAM)
CA (1) CA1202639A (OSRAM)
DE (1) DE3263734D1 (OSRAM)
ES (1) ES512842A0 (OSRAM)
FR (1) FR2508035A1 (OSRAM)
LU (1) LU90410I2 (OSRAM)
ZA (1) ZA824453B (OSRAM)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2581059B1 (fr) * 1985-04-25 1988-04-22 Pf Medicament Procede de preparation du chlorhydrate de phenyl-1 diethyl amino carbonyl-1 aminomethyl-2 cyclopropane (z)
FR2581060B1 (fr) * 1985-04-25 1988-07-01 Pf Medicament Procede industriel d'obtention du midalcipran
EP0747348A4 (en) * 1994-02-22 1999-07-07 Asahi Chemical Ind AMINOALKYLCYCLOPROPAN DERIVATIVES
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
DK0759299T3 (da) * 1995-08-16 2000-08-07 Lilly Co Eli Potensering af serotoninrespons
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
MXPA04003358A (es) * 2001-10-12 2004-07-08 Serenix Pharmaceuticals Llc Antagonistas de vasopresina v1a de ?-lactamilo.
US6635675B2 (en) * 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
CA2483093A1 (en) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain
CA2503381A1 (en) * 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
PT1601349E (pt) 2003-02-14 2008-10-27 Pf Medicament Utilização do enantiómero (1s, 2r) do milnaciprano para a preparação de um medicamento
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
MXPA05011225A (es) * 2003-04-18 2005-12-14 Pharmacia & Upjohn Co Llc Politerapias.
BRPI0413584A (pt) * 2003-08-15 2006-10-17 Lundbeck & Co As H composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de doenças e para tratamento de um distúrbio no sistema nervoso central
ATE528291T1 (de) * 2003-08-15 2011-10-15 Lundbeck & Co As H Cyclopropylderivate als nk3 rezeptor-antagonisten
ES2515092T3 (es) 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
JP4418717B2 (ja) * 2004-06-24 2010-02-24 住友化学株式会社 （ｚ）−１−フェニル−１−ジエチルアミノカルボニル−２−アミノメチルシクロプロパン塩酸塩の製造方法
AU2006227199A1 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
CN101203216A (zh) * 2005-04-22 2008-06-18 惠氏公司 二氢苯并呋喃衍生物及其用途
CN101203218A (zh) * 2005-04-22 2008-06-18 惠氏公司 苯并呋喃基链烷胺衍生物和其作为5－ht2c激动剂的用途
CN101175740A (zh) * 2005-04-22 2008-05-07 惠氏公司 二氢苯并呋喃衍生物和其用途
CA2611724C (en) * 2005-06-10 2014-07-29 Pierre Fabre Medicament S.A. Stabilized milnacipran formulation
SG163588A1 (en) * 2005-07-08 2010-08-30 Braincells Inc Methods for identifying agents and conditions that modulate neurogenesis
CA2615813C (en) * 2005-07-19 2015-12-15 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
US20090203750A1 (en) * 2005-08-24 2009-08-13 Alan Kozikowski 5-HT2C Receptor Agonists as Anorectic Agents
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
AU2007208681B2 (en) * 2006-01-27 2010-04-08 Asahi Kasei Pharma Corporation Medicine for transnasal administration
US20080319083A1 (en) * 2006-01-27 2008-12-25 Asahi Kasei Pharma Corporation Medicine for transnasal administration
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007231011A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
CA2662491A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
CA2675132A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
EP2114868A2 (en) * 2007-02-28 2009-11-11 Ranbaxy Laboratories Limited Novel polymorphic forms of milnacipran hydrochloride
WO2009023820A1 (en) * 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Improving the tolerability of a serotonin antagonist and a nsri, a snri or a rima by using them in combination
US20090069431A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched milnacipran
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010036773A1 (en) * 2008-09-24 2010-04-01 Concert Pharmaceuticals, Inc. Deuterated l-aryl-2 -aminomethyl cyclopropane carboxyamide derivatives
FR2941454B1 (fr) 2009-01-29 2011-04-01 Pf Medicament Proced de synthese du (1s,2r)-milnacipran
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20100274050A1 (en) * 2009-04-23 2010-10-28 Glenmark Generics Limited Solid milnacipran and process for the preparation of the same
WO2010129689A1 (en) * 2009-05-05 2010-11-11 Forest Laboratories Holdings Limited Milnacipran formulations
EP2461801A2 (en) 2009-08-05 2012-06-13 Lupin Limited Controlled release pharmaceutical compositions of milnacipran
EP2496079A4 (en) * 2009-11-06 2014-05-14 Pierre Fabre Médicament Sas NOVEL (1S, 2R) -2- (AMINOMETHYL) -N, N-DIETHYL-1-PHENYLCYCLOPROPANECARBOXAMIDE CRYSTALLINE FORMS
WO2011092065A1 (en) 2010-01-29 2011-08-04 Nicox S.A. Nitric oxide releasing compounds for the treatment of neurophatic pain
CN107007596A (zh) 2010-07-01 2017-08-04 阿泽凡药物公司 用于治疗创伤后应激障碍的方法
US8916194B2 (en) 2010-08-30 2014-12-23 Lupin Limited Controlled release pharmaceutical compositions of milnacipran
WO2012059933A1 (en) 2010-11-03 2012-05-10 Arch Pharmalabs Limited A new process for preparing optically pure milnacipran and its pharmaceutically acceptable salts.
WO2012145234A2 (en) 2011-04-21 2012-10-26 Emory University Cyclopropyl derivatives and methods of use
WO2014009767A1 (en) 2012-07-07 2014-01-16 Micro Labs Limited An improved process for the preparation of 1-aryl 2-aminomethyl cyclopropane carboxyamide (z) derivatives, their isomers and salts
WO2014203277A2 (en) * 2013-06-19 2014-12-24 Msn Laboratories Private Limited Process for the preparation of (1s,2r)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanearboxamide hydrochloride
IN2013MU03122A (OSRAM) 2013-09-30 2015-07-17 Cadila Healthcare Ltd
NZ724718A (en) 2014-03-28 2023-04-28 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
WO2019055913A1 (en) 2017-09-15 2019-03-21 Azevan Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY
MX2022000709A (es) 2019-07-19 2022-05-19 Bioxcel Therapeutics Inc Regimenes de tratamiento con dexmedetomidina no sedante.
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA619080A (en) * 1961-04-25 The Upjohn Company N-SUBSTITUTED-.alpha.-(TERTIARY-AMINOALKYL)-.alpha.-PHENYLACETAMIDES
CA570688A (en) * 1959-02-17 E. Speeter Merrill Antispasmodic substituted amines
GB1415541A (en) 1972-11-30 1975-11-26 Hexachimie 1-amino-methyl-2,2-diarylcyclopropanecarboxamide

Also Published As

Publication number Publication date
US4478836A (en) 1984-10-23
ES8303293A1 (es) 1983-03-01
FR2508035B1 (OSRAM) 1984-06-29
JPS584752A (ja) 1983-01-11
JPS6323186B2 (OSRAM) 1988-05-16
ZA824453B (en) 1983-04-27
ATE13422T1 (de) 1985-06-15
LU90410I2 (fr) 1999-08-31
ES512842A0 (es) 1983-03-01
AU8508682A (en) 1983-01-06
EP0068999A1 (fr) 1983-01-05
CA1202639A (fr) 1986-04-01
EP0068999B1 (fr) 1985-05-22
DE3263734D1 (en) 1985-06-27
FR2508035A1 (fr) 1982-12-24

Similar Documents

Publication Publication Date Title
AU550774B2 (en) 1-aryl-2-aminomethyl cyclopropane carboxylates
ATE127801T1 (de) Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung.
CU22305A3 (es) Procedimiento para la preparacion de un derivado de aminoacidos
NZ238181A (en) N-(1-substituted-piperidinyl(alkyl))carbamic acid, urea and carboxamide derivatives and homologues thereof; preparatory processes and pharmaceutical compositions
ES8103744A1 (es) Un metodo para la preparacion de derivados de ftalimidina
PT76450A (de) Spiro/4.(3+n)-2-aza-3-carbonsaeure-derivate verfahren zu ihrer herstellung diese enthaltende mittel und ihre verwendung
ES538418A0 (es) Un derivado de indol-3-carboxamida
DK519985D0 (da) Quinoloncarboxylsyrederivater, fremgangsmaade til fremstilling deraf og antibakterielt middel indeholdende saadanne derivater
DE3882438D1 (de) Alkansulfonanilid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung.
FI101301B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten, N-substituoitujen heksahydroatsepiinijohdannaisten valmistamiseksi
ES544417A0 (es) Procedimiento para preparar 8-alquiltio-2-piperazino-pirimido(5,4-d)pirimidinas.
PT93450A (pt) Processo para a preparacao de novos derivados azetidinicos de acidos piridinocarboxilicos e de composicoes farmaceuticas que os contem
ES8301460A1 (es) Un procedimiento para la preparacion de l-amino acidos n-sustituidos.
DK469285D0 (da) Thiadiazolderivater, der indvirker paa centralnervesystemet, fremgangsmaade til fremstilling deraf og midler indeholdende derivaterne
HUT38948A (en) Process for preparing new isoxazolo-quinolinone derivatives and pharmaceutical compositions containing such compounds
ES8307798A1 (es) Un procedimiento para la preparacion de derivados de piperazilmetil-4-dibenzofuranona, o, dibenzofuranol.
IL70558A (en) 1-(aminoalkoxyphenyl)-1-phenylpropanols,their preparation and pharmaceutical compositions containing them
AU1621392A (en) New 1-amidooctahydropyrido(2,1-c)(1,4)oxazine compounds, processes for preparing these and pharmaceutical compositions containing them
IT1261958B (it) 2-(sostituite immino)-tiazolidine e procedimento per la loro preparazione e loro impiego quali antianginose e/o analgesiche

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired